Tag: Conditions

  • Autonomous on-demand buses underway in the streets of Europe

    Autonomous on-demand buses underway in the streets of Europe

    Would you like to take a ride on a driverless bus? This will be possible in five European cities between April and October 2020, where autonomous buses will be tested in real-life traffic conditions. Three international consortia have been awarded with contracts for the final phase of the pre-commercial procurement under the EU-funded FABULOS project. These consortia will pilot autonomous buses as part of the existing public transport systems. The initial tests will run in Gjesdal (Norway), Helsinki (Finland) and Tallinn (Estonia) in the spring and autumn. Pilots will also be launched in Lamia (Greece) and Helmond (the Netherlands).

    Read More

    Views: 0

  • Ultrathin organic solar cell is efficient and durable

    Ultrathin organic solar cell is efficient and durable

    Scientists from the RIKEN, in collaboration with international partners, have succeeded in creating an ultrathin organic solar cell that is both highly efficient and durable. Using a simple post-annealing process, they created a flexible organic cell that degrades by less than 5 percent over 3,000 hours in atmospheric conditions and that simultaneously has an energy conversion ratio—a key indicator of solar cell performance—of 13 percent.

    Read More

    Views: 0

  • WHO steps up action to improve access to safe blood

    WHO steps up action to improve access to safe blood

    The World Health Organization’s new action plan to speed up universal access to safe blood and blood products pulls together existing recommendations and recommends new improved ways of working. It’s the start of a four-year collaborative effort to improve blood transfusion and blood-based therapies in all countries.

    Safe blood saves lives in all sorts of circumstances, not least in emergency and epidemic settings. Blood transfusion and blood products are critical for birth delivery for both the mother and baby; the survival and quality of life of patients suffering from life-threatening conditions such as haemophilia, thalassemia, immune deficiency and cancer; treating severe injuries and carrying out medical and surgical procedures.  

    But progress in blood safety and availability has been slow in many parts of the world, placing patients’ safety at risk and putting undue pressure on health workers. Progress is also mostly restricted to developed countries. Out of the approximate 118 million blood donations collected globally, 42% are collected in high-income countries, home to 16 % of the world’s population. And one out of four low-income countries do not test all donated blood, while 54% of countries do not have surveillance systems to securitise the supply chain from blood donor to patient. 

    Challenges include: slow implementation of national blood policies and weak blood regulatory systems; insufficient number of voluntary blood donors (who are considered the safest donors); poor quality management of screening tests, blood grouping and compatibility testing; inappropriate clinical use of blood; insufficient national funding for blood safety.

    To address these, WHO has set out six key objectives for all countries and in particular those with weak blood systems:

    • appropriately structured, well-coordinated and sustainably resourced national blood systems;
    • regulatory capacity to ensure the quality and safety of blood;
    • functioning and efficiently managed blood services;
    • effective implementation of patient blood management to optimize transfusion practices;
    • effective surveillance, haemovigilance and pharmacovigilance, supported by comprehensive and accurate data collection systems;
    • partnerships, collaboration and information exchange to achieve key priorities and jointly address challenges and emerging threats at global, regional and national levels.

    The Organization looks forward to working with partners worldwide to implement the plan, improve blood supply particularly in the low and middle-income countries where this is so urgently needed, and save lives. The plan will run from 2020-2024.

    WHO steps up action to improve access to safe blood
    Read More
    https://www.who.int/news-room/detail/26-02-2020-who-steps-up-action-to-improve-access-to-safe-blood

    Views: 0

  • WHO launch eEML

    WHO launch eEML

    The World Health Organization has launched a new easy-to-access, digital version of its Model list of Essential Medicines (EML). The move will revolutionize the way this core WHO reference tool is used.

    More than 150 countries currently use the WHO list to work out which medicines best meet their national health contexts and priorities, so they can compile their own national essential medicines lists.

    Essential medicines are those that satisfy the priority health care needs of a population. They are the medicines that need to be available in a functioning health system at all times, in appropriate dosage forms, of assured quality, and at prices individuals and the community can afford.

    Keeping up-to-date lists of the most important medicines a country needs is key to achieving health for all in a sustainable way.

    Since 1977, the WHO list has been revised every 2 years (most recently in 2019) by a group of experts and published in print or PDF formats. It includes information about available dose forms and strengths; specifications as to who should take a medicine; what conditions a medicine can treat and how it should be taken, as well as details about the clinical evidence supporting recommendations being made.

    The new electronic version brings the traditional EML to smartphones and computer screens in a comprehensive, freely accessible, online database. Instead of flicking through pages of information, users can search by simply clicking on the name of a medicine, for example, or a health issue. They can also make their own customized lists by exporting the list – in full or in part – into an Excel or Word version.  

    The electronic EML is the latest step in WHO’s effort to harness digital technologies to drive improvements in global public health, and advance progress towards universal health coverage. 

     

    WHO launch eEML
    Read More
    https://www.who.int/news-room/detail/27-02-2020-who-launch-e-eml

    Views: 0

  • The economic cost of female genital mutilation

    The economic cost of female genital mutilation

    An interactive data tool launched by WHO reveals for the first time the current and future financial cost of health care for women living with conditions caused by female genital mutilation (FGM).

    The total costs amount to USD 1.4 billion annually.

    fgm-cost-thumbnail

    The FGM Cost Calculator is being launched on this year’s International Day of Zero Tolerance for FGM. This new tool shows that if FGM were abandoned now the associated savings
    in health costs would be more than 60% by 2050. This data, available for 27 of the 30 countries where FGM is practiced, will strengthen the economic argument of community activists, policy makers, programme planners and donors working to end this
    human rights violation.

    Q&As on the FGM Cost Calculator
    Access the FGM Cost Calculator

    A human rights violation with economic costs

    FGM includes procedures that intentionally alter or cause injury to the female genital organs for non-medical reasons. More than 200 million girls and women alive today have been cut in 30 countries in Africa, the Middle East and Asia where FGM is concentrated.
    [1] An extreme form of gender discrimination, it is recognized internationally as a violation of the human rights of girls and women: including the right to health, security and physical integrity and the right to be free from torture and cruel, inhuman
    or degrading treatment.

    FGM has no health benefits and causes only harm. Women and girls who are subjected to FGM are at risk of both short- and long-term negative health consequences – including for their physical, sexual, mental, and social well-being.

    The direct financial cost of treating the negative health complications caused by FGM can span generations, starting as early as childbirth. This puts a significant economic burden on health systems and national budgets, especially in countries with rates
    of FGM greater than 10%.

    Until now, there have been limited data on the financial costs associated with FGM, making it hard to demonstrate the cost-effectiveness of programmes and policies that can prevent FGM by 2030 – a global priority in the Sustainable Development Agenda.
    The new WHO Cost Calculator now provides an economic argument which can be used by those advocating for an end to FGM.

    Calculating health care costs of FGM

    Users of the new FGM Cost Calculator can choose a country and identify current costs of treating health conditions caused by FGM. Since the tool is interactive, it produces bespoke graphs showing the potential amount of money saved if FGM is prevented
    by a selected percentage.

    If no action is taken to prevent FGM, it is estimated that related health costs will soar by 50% by 2050, as populations grow and as more girls undergo the procedure.

    How it works

    The FGM Cost Calculator combines data on health risk associated with FGM, health costs and national FGM prevalence to analyze the economic impact on national health services of treating the consequences of these harmful practices.

    Health risk data were taken from a WHO database created for this analysis, pooling all available information from systematic reviews of health consequences of FGM. The following categories were used, each with a biological link to FGM: gynaecological,
    obstetric, urological, mental and sexual, as well as the immediate health complications that can result following the cutting.

    To be included in the calculator, a health condition needed to show evidence of increased risk when comparing women with and without FGM. It also needed to have a treatment which could be implemented and costed in the health sector.

    Health costs were calculated from the WHO One Health Tool and other data. The financial burden of treating selected health conditions was calculated at a national level.

    A strong case for investment in preventing FGM

    Rates of FGM have declined over the past 30 years, but not fast enough to keep up with population growth. If trends continue, the number of girls and women undergoing FGM will rise significantly in the next 15 years, in turn raising national health care
    costs of caring for them.

    Additional resources are urgently needed to scale up interventions that can prevent FGM in the future and reduce health complications.

    By providing quantifiable numbers on the cost of treating health conditions directly linked to FGM, for the first time, the FGM Cost Calculator can be a crucial tool in building an investment case for a future where no girl or woman is cut.


    [1] Female Genital Mutilation/Cutting: A Global Concern, UNICEF, New York, 2016
    The economic cost of female genital mutilation
    Read More
    https://www.who.int/news-room/detail/06-02-2020-economic-cost-of-female-genital-mutilation

    Views: 0

  • Pregnancy and breastfeeding during an Ebola virus outbreak

    Pregnancy and breastfeeding during an Ebola virus outbreak

    Women who are pregnant or breastfeeding in an Ebola outbreak face similar challenges as other population groups, but they have specific health needs which must be met.

    As the second largest Ebola outbreak in history continues in the Democratic Republic of Congo, WHO has released new clinical guidelines for healthcare providers supporting pregnant or breastfeeding women in the context of Ebola virus disease.

    Improving clinical care and reducing mortality

    92-4-000138-1Clear and coherent guidance is needed to meet the combined needs of women requiring Ebola treatment, pregnancy care and management of complications.

    Information on how to protect breastfeeding children and other members in the community from transmission of the disease is also critical.

    Limited scientific evidence on how to best manage these needs has previously been a challenge for affected countries. In addition, misconceptions that pregnant women have a higher mortality rate than other populations with Ebola may in some contexts have put pregnant women at risk of not receiving standard care.

    WHO’s Guideline on the management of pregnant and breastfeeding women in the context of Ebola virus reviews existing evidence and provides a single set of recommendations on the care continuum for women exposed to, diagnosed with, or recovered from Ebola.

    This will enable healthcare providers, emergency response teams and health policy-makers to improve prevention and treatment measures in an Ebola outbreak.

    Obstetric care at an Ebola Treatment Centre

    Optimal supportive care should be offered to all pregnant women with Ebola. Likewise, they should be offered experimental treatment and vaccination under the same conditions as non-pregnant populations.

    Ebola virus disease does increase the risk of miscarriage and early labour, requiring close clinical management at Ebola treatment centres. It is important to engage both obstetric providers and those trained in Ebola response.

    This dual expertise is also important because early Ebola and pregnancy-related symptoms can overlap. Pregnant women should be prioritised for testing to confirm an Ebola infection.

    Ebola virus can persist in pregnancy related fluids as well as breastmilk. If healthcare providers are not clear on how to manage Ebola infection risk, they may be less willing to provide care. This stigma can be life-threatening for women who experience complications during delivery.

    The new WHO guidelines advise healthcare workers on how to protect themselves while caring for pregnant women with Ebola virus disease. This includes induced labour or surgical procedures, which carry greater risk of transmission in cases of acute infection. Any invasive treatments should be carried out in full personal protective equipment.

    Breastfeeding recommendations in an Ebola outbreak

    WHO recommends that women with suspected or confirmed Ebola immediately stop breastfeeding and are prioritised for diagnostic testing. Any child exposed to Ebola through breast milk should be placed into safe care, closely monitored for symptoms over a 21-day period and fed with an appropriate breast milk substitute.  

    The guidelines strongly recommend that breastfeeding is only restarted following two consecutive negative tests of breast milk, separated by 24 hours.

    A breast milk substitute should be used even if infection is confirmed for both the mother and her child. Exceptions can be made for infants under 6 months of age who are already infected, if breast milk substitutes are not feasible, affordable, sustainable or safe and separation cannot be implemented safely.

    Women’s health and rights in a disease outbreak

    A disease outbreak does not change women’s and adolescent girls’ fundamental human right to sexual and reproductive healthcare, including evidence-based care during pregnancy and childbirth.

    Women need support to make informed reproductive health care choices for themselves and their children. Women living in an Ebola outbreak should have access to all relevant reproductive options, regardless of economic, cultural, racial or religious status, including contraception and safe abortion to the full extent of the law.

    Pregnant and breastfeeding women across affected communities need equitable and respectful care that considers the risks they face and supports the choices they make.

    Accessing the guidelines and further research

    These guidelines are now available online and may be freely downloaded. The executive summary will be available in French.

    WHO will closely monitor new data as it emerges, as there is still a pressing need to prioritise ongoing research related to Ebola virus transmission.

     

     

     

    Pregnancy and breastfeeding during an Ebola virus outbreak
    Read More
    https://www.who.int/news-room/detail/10-02-2020-pregnancy-and-breastfeeding-during-an-ebola-virus-outbreak

    Views: 0

  • Female Genital Mutilation Hurts Women and Economies

    Female Genital Mutilation Hurts Women and Economies

    Female genital mutilation (FGM) exacts a crippling economic as well as human cost, according to World Health Organization (WHO).

    “FGM is not only a catastrophic abuse of human rights that significantly harms the physical and mental health of millions of girls and women; it is also a drain on a country’s vital economic resources,” said Dr Ian Askew, Director of WHO’s Department of Sexual and Reproductive Health and Research. “More investment is urgently needed to stop FGM and end the suffering it inflicts.”

    New modelling reveals that the total costs of treating the health impacts of FGM would amount to USD 1.4 billion globally per year, if all resulting medical needs were addressed. For individual countries, these costs would near 10% of their entire yearly expenditure on health on average; in some countries, this figure rises to as much as 30%.

    The interactive modelling tool that generated these data was launched on the International Day of Zero Tolerance for Female Genital Mutilation.

    Severe physical and mental health impacts for women and girls

    Women and girls living with FGM face serious risks to their health and well-being. These include immediate consequences after being cut, such as infections, bleeding or psychological trauma, as well as chronic health conditions that can occur throughout life.

    Women who have undergone the procedure are more likely to experience life-threatening complications during childbirth. They may face mental health disorders or suffer chronic infections. They may also have pain or problems when they menstruate, urinate or have sexual intercourse. 

    All of these conditions warrant much-needed medical attention and care.

    “High healthcare costs for countries mount because of the tragic personal impacts on women and girls. Governments have a moral responsibility to help end this harmful practice,” says Dr Prosper Tumusiime, Acting Director for Universal Health Coverage and the Life Course in the African Regional Office of WHO. “FGM hurts girls, imposes lifelong health risks on the women they become, and strains the healthcare systems that need to treat them.”

    Preventing FGM brings major benefits for women, girls, communities and economies

    Using data from 27 high-prevalence countries, the Cost Calculator demonstrates clear economic benefits from ending FGM. If it were abandoned now, it shows that the associated savings in health costs would be more than 60% by 2050.

    In contrast, if no action is taken, it is estimated that these costs will soar by 50% over the same time period, as populations grow and as more girls undergo the procedure.

    Since 1997, great efforts have been made to end FGM, through work within communities, research, and changes in legislation and policy. 26 countries in Africa and the Middle East now explicitly legislate against FGM, as well as 33 other countries with migrant populations from FGM-practicing countries.

    WHO is also working with countries to raise awareness of the harmful impacts of the practice among their health workers, and to engage them in prevention efforts.

    “Many countries and communities are showing that abandoning female genital mutilation is possible,” states Dr Christina Pallitto, scientist at WHO. “If countries invest to end female genital mutilation, they can prevent their girls from undergoing this harmful practice and promote the health, rights and well-being of women and girls.”

    Female genital mutilation is internationally recognized as a human rights violation. It has no medical benefits and causes only harm. WHO’s position is that FGM must never be carried out.

    Further information

    The FGM Cost Calculator will be available here, as of 00:30 CET 6 February 2020:
    www.who.int/news-room/detail/06-02-2020-economic-cost-of-female-genital-mutilation

    More on FGM

    Notes for Editors

    About FGM

    FGM includes procedures that intentionally alter or cause injury to the female genital organs for non-medical reasons. More than 200 million girls and women alive today are estimated to have undergone the practice across 30 countries in Africa, the Middle East and Asia where FGM is concentrated.

    FGM is mostly carried out on young girls between infancy and 15 years of age.

    About the FGM Cost Calculator

    The WHO FGM Cost Calculator shows the economic cost of treating the health complications caused by FGM across 27 high-prevalence countries. These costs were calculated using the WHO One Health tool and other available scientific evidence.

    Users of the tool can calculate costs by country in a ‘business as usual’ scenario; a scenario of partial abandonment of FGM, and full abandonment of FGM over a 30-year period. In addition, the distribution of costs by different types of health complications is presented by country.

    The tool does not consider other indirect costs that hit families and communities, or the socio-economic impacts of the practice, which would be significantly higher still.

    The 27 countries modelled include Benin, Burkina Faso, Central African Republic, Còte d’Ivoire, Cameroon, Chad, Djibouti, Egypt, Eritrea, Ethiopia, Ghana, Guinea, Gambia, Guinea-Bissau, Iraq, Kenya, Mali, Mauritania, Niger, Nigeria, Soudan, Senegal, Sierra Leone, Somalia, Togo, United Republic of Tanzania, Yemen.

    Female Genital Mutilation Hurts Women and Economies
    Read More
    https://www.who.int/news-room/detail/06-02-2020-female-genital-mutilation-hurts-women-and-economies

    Views: 0

  • Preventing child obesity in the next generation must start before conception

    Preventing child obesity in the next generation must start before conception

    The key to preventing obesity in future generations is to make their parents healthier before they conceive, leading health researchers suggest.

    In a series of papers, published in The Lancet Diabetes and Endocrinology, the researchers say that the time before couples conceive represents a missed opportunity to prevent the transmission of obesity risk from one generation to the next. They argue that a new approach is needed to motivate future parents to live a healthier lifestyle.

    There is now a wealth of evidence that the risk of obesity and its associated conditions, such as heart disease diabetes and some cancers, could impact the developing baby. In turn, when the child becomes a young adult they may pass the risk of obesity on to their children – it is a vicious cycle.

    Views: 0